FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385306388> ?p ?o ?g. }

• W4385306388 endingPage "1444" @default.
• W4385306388 startingPage "1436" @default.
• W4385306388 abstract "Crizotinib has been approved for C-ros oncogene 1 (ROS1)- and anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer (NSCLC) patients. Few studies have examined the differences in crizotinib treatment outcomes between these patients and the progression sites during treatment. We investigated the metastatic spread, crizotinib efficacy, and progression patterns during crizotinib treatment in ROS1- and ALK-rearranged NSCLC patients.We retrospectively reviewed crizotinib-treated ROS1- and ALK-rearranged NSCLC patients between January 2011 and March 2021. Patient characteristics, clinical outcomes, and progression patterns during treatment were collected from medical records. The metastasis extent, crizotinib response, and progression patterns between the groups were compared.We identified 26 patients with ROS1- and 42 with ALK-positive NSCLC. The baseline proportion of central nervous system (CNS) metastases did not differ between the groups (12% vs. 29%, P=0.10), but the proportion of extrathoracic metastases, including CNS metastases, was significantly higher in ALK-positive than in ROS1-positive NSCLC patients (35% vs. 71%, P=0.003). Regarding the response to crizotinib, the objective response rate (ORR), progression-free survival (PFS), or overall survival (OS) did not significantly differ between the groups (ROS1vs.ALK, ORR: 69% vs. 69%, P=0.987; PFS: median 10.9 vs. 10.7 months, P=0.232; median OS: not reached vs. 67.7 months, P=0.495). The CNS was the most common metastasis site in both groups [ROS1vs.ALK, 69% (11/16) vs. 46% (17/37), P=0.127], and the cumulative incidence of CNS metastasis did not differ between the groups (P=0.914).Crizotinib treatment outcomes, including progression patterns, were similar between ROS1- and ALK-positive NSCLC patients." @default.
• W4385306388 created "2023-07-28" @default.
• W4385306388 creator A5002845200 @default.
• W4385306388 creator A5016850482 @default.
• W4385306388 creator A5026743645 @default.
• W4385306388 creator A5030587345 @default.
• W4385306388 creator A5033956905 @default.
• W4385306388 creator A5050085436 @default.
• W4385306388 creator A5064362444 @default.
• W4385306388 creator A5069589468 @default.
• W4385306388 creator A5081785503 @default.
• W4385306388 creator A5090846902 @default.
• W4385306388 creator A5092553008 @default.
• W4385306388 date "2023-07-01" @default.
• W4385306388 modified "2023-09-26" @default.
• W4385306388 title "Distinct metastatic spread and progression patterns in patients treated with crizotinib for ROS1- and ALK-rearranged non-small cell lung cancer: a single-center retrospective study" @default.
• W4385306388 cites W1712727770 @default.
• W4385306388 cites W1981258651 @default.
• W4385306388 cites W1990626198 @default.
• W4385306388 cites W2014633738 @default.
• W4385306388 cites W2019607817 @default.
• W4385306388 cites W2050249255 @default.
• W4385306388 cites W2099530756 @default.
• W4385306388 cites W2103110584 @default.
• W4385306388 cites W2130488043 @default.
• W4385306388 cites W2147038864 @default.
• W4385306388 cites W2149592447 @default.
• W4385306388 cites W2339561092 @default.
• W4385306388 cites W2745391639 @default.
• W4385306388 cites W2784586990 @default.
• W4385306388 cites W2794491531 @default.
• W4385306388 cites W2800286167 @default.
• W4385306388 cites W2805535665 @default.
• W4385306388 cites W2846588575 @default.
• W4385306388 cites W2938245541 @default.
• W4385306388 cites W2938369148 @default.
• W4385306388 cites W2967992516 @default.
• W4385306388 cites W3112504741 @default.
• W4385306388 cites W3169646530 @default.
• W4385306388 doi "https://doi.org/10.21037/tlcr-23-10" @default.
• W4385306388 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37577313" @default.
• W4385306388 hasPublicationYear "2023" @default.
• W4385306388 type Work @default.
• W4385306388 citedByCount "0" @default.
• W4385306388 crossrefType "journal-article" @default.
• W4385306388 hasAuthorship W4385306388A5002845200 @default.
• W4385306388 hasAuthorship W4385306388A5016850482 @default.
• W4385306388 hasAuthorship W4385306388A5026743645 @default.
• W4385306388 hasAuthorship W4385306388A5030587345 @default.
• W4385306388 hasAuthorship W4385306388A5033956905 @default.
• W4385306388 hasAuthorship W4385306388A5050085436 @default.
• W4385306388 hasAuthorship W4385306388A5064362444 @default.
• W4385306388 hasAuthorship W4385306388A5069589468 @default.
• W4385306388 hasAuthorship W4385306388A5081785503 @default.
• W4385306388 hasAuthorship W4385306388A5090846902 @default.
• W4385306388 hasAuthorship W4385306388A5092553008 @default.
• W4385306388 hasBestOaLocation W43853063881 @default.
• W4385306388 hasConcept C117643217 @default.
• W4385306388 hasConcept C121608353 @default.
• W4385306388 hasConcept C126322002 @default.
• W4385306388 hasConcept C143998085 @default.
• W4385306388 hasConcept C2775999482 @default.
• W4385306388 hasConcept C2776232967 @default.
• W4385306388 hasConcept C2776256026 @default.
• W4385306388 hasConcept C2776694085 @default.
• W4385306388 hasConcept C2778164965 @default.
• W4385306388 hasConcept C2778347629 @default.
• W4385306388 hasConcept C2779013556 @default.
• W4385306388 hasConcept C2779422266 @default.
• W4385306388 hasConcept C2780739268 @default.
• W4385306388 hasConcept C2781182431 @default.
• W4385306388 hasConcept C71924100 @default.
• W4385306388 hasConceptScore W4385306388C117643217 @default.
• W4385306388 hasConceptScore W4385306388C121608353 @default.
• W4385306388 hasConceptScore W4385306388C126322002 @default.
• W4385306388 hasConceptScore W4385306388C143998085 @default.
• W4385306388 hasConceptScore W4385306388C2775999482 @default.
• W4385306388 hasConceptScore W4385306388C2776232967 @default.
• W4385306388 hasConceptScore W4385306388C2776256026 @default.
• W4385306388 hasConceptScore W4385306388C2776694085 @default.
• W4385306388 hasConceptScore W4385306388C2778164965 @default.
• W4385306388 hasConceptScore W4385306388C2778347629 @default.
• W4385306388 hasConceptScore W4385306388C2779013556 @default.
• W4385306388 hasConceptScore W4385306388C2779422266 @default.
• W4385306388 hasConceptScore W4385306388C2780739268 @default.
• W4385306388 hasConceptScore W4385306388C2781182431 @default.
• W4385306388 hasConceptScore W4385306388C71924100 @default.
• W4385306388 hasIssue "7" @default.
• W4385306388 hasLocation W43853063881 @default.
• W4385306388 hasLocation W43853063882 @default.
• W4385306388 hasLocation W43853063883 @default.
• W4385306388 hasOpenAccess W4385306388 @default.
• W4385306388 hasPrimaryLocation W43853063881 @default.
• W4385306388 hasRelatedWork W1592240224 @default.
• W4385306388 hasRelatedWork W2400744927 @default.
• W4385306388 hasRelatedWork W2516942920 @default.
• W4385306388 hasRelatedWork W2951811716 @default.
• W4385306388 hasRelatedWork W2976571964 @default.

• next